EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Challenges in HER2-low breast cancer identification, detection, and treatment

Qian Wu iD, Ling Xu iD

Translational Breast Cancer Research · 2024-01 · 5 · 3-3

DOI: 10.21037/tbcr-23-48 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Translational Breast Cancer Research, 2024-01. Verfasst von Qian Wu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Thyroid and Breast Surgery, Peking University First Hospital, Beijing, China. Die Arbeit wurde bisher 9-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recently, human epidermal growth factor receptor 2 (HER2)-low breast cancer (BC) has emerged as a novel subset within the category of HER2-negative BC, prompting a reassessment of the immunohistochemical negative scores of 0, 1+, and the 2+/in situ hybridization (ISH) negative phenotype. Recent clinical trials have provided compelling evidence of the substantial clinical advantages offered by novel antibody-drug conjugates (ADCs) that target HER2 in the treatment of these specific tumor cohorts. Notably, trastuzumab deruxtecan (T-Dxd), an ADC that specifically targets HER2, has recently received approval from the US Food and Drug Administration as the inaugural targeted therapeutic option for HER2-low BC. However, the classification of HER2-low BC as a distinct subtype, the methods for detecting HER2-low BC, and the optimal treatment approach for HER2-low BC remain subjects of ongoing debate and lack consensus. This comprehensive review aims to address these pertinent concerns, offering insights into the nuanced tumor biology underlying HER2-low BC and critically analyzing the current treatment pathways available. By synthesizing available evidence, the objective is to contribute to an enhanced understanding of HER2-low BC, providing a foundation for more informed clinical decisions and further advancements in tailored therapeutic approaches. As the medical community navigates these uncertainties, this review seeks to consolidate existing knowledge, fostering a collective effort toward establishing consensus in the diagnosis and treatment of HER2-low BC.

Schlagwörter

Stichwörter der Autor:innen

Human epidermal growth factor receptor 2 low (HER2-low)breast cancer (BC)diagnosistreatment

Autor:innen und Institutionen

  • Thyroid and Breast Surgery, Peking University First Hospital, Beijing, China.

ORCID-Profile: Qian Wu, Ling Xu

Zitieren

APA

Wu, Q., & Xu, L. (2024). Challenges in HER2-low breast cancer identification, detection, and treatment. Translational Breast Cancer Research, 5, 3-3. https://doi.org/10.21037/tbcr-23-48

Vancouver

Wu Q, Xu L. Challenges in HER2-low breast cancer identification, detection, and treatment. Translational Breast Cancer Research. 2024;5:3-3. doi:10.21037/tbcr-23-48

BibTeX
@article{Wu2024,
  author = {Wu, Qian and Xu, Ling},
  title = {Challenges in HER2-low breast cancer identification, detection, and treatment},
  journal = {Translational Breast Cancer Research},
  year = {2024},
  volume = {5},
  pages = {3--3},
  doi = {10.21037/tbcr-23-48}
}
Kostenlos starten →